Cullen Michael W, Stein James H, Gangnon Ronald, McBride Patrick E, Keevil Jon G
Department of Internal Medicine, Mayo School of Graduate Medical Education, Rochester, MN.
Am Heart J. 2008 Aug;156(2):284-91. doi: 10.1016/j.ahj.2008.03.004. Epub 2008 Jun 4.
This study sought to evaluate national levels of elevated low-density lipoprotein cholesterol (LDL-C) before and after publication of the Adult Treatment Panel III (ATP III). The ATP III guidelines intensified LDL-C targets and defined additional high-risk conditions. These recommendations are expected to have a noticeable impact on US cholesterol levels.
Coronary heart disease (CHD) risk was determined per ATP III guidelines for US residents aged 20 to 79 years in the 1999 to 2000 and 2001 to 2002 surveys. For those at high risk, the LDL-C mean percentage <100 mg/dL and percentage > or =130 mg/dL, although not taking lipid-lowering therapy, were compared between the 2 surveys. In addition, subsets with and without CHD were evaluated.
Of all high-risk US residents, the mean LDL-C dropped from 129 mg/dL in 1999 to 2000 to 120 mg/dL in 2001 to 2002 (P = .003). Those <100 mg/dL increased from 23% to 32% (P = .003). Those > or =130 mg/dL and not on medication dropped from 36% to 27% (P = .001). Goal achievement and improvements were more favorable in the subset with CHD compared with those at high risk due to high-risk equivalent conditions.
The sharp increase in high-risk US residents at the goal and the drop in the untreated percentage of those above treatment threshold illustrate national improvements in the management of LDL-C for those at high coronary risk. High-risk subjects without CHD displayed less significant improvements, suggesting an opportunity for better recognition and management of these individuals.
本研究旨在评估成人治疗小组第三次报告(ATP III)发布前后全国范围内低密度脂蛋白胆固醇(LDL-C)升高的情况。ATP III指南强化了LDL-C目标并定义了额外的高危情况。预计这些建议将对美国的胆固醇水平产生显著影响。
根据ATP III指南,在1999至2000年以及2001至2002年的调查中确定了20至79岁美国居民的冠心病(CHD)风险。对于高危人群,比较了两次调查中LDL-C平均百分比<100mg/dL以及≥130mg/dL(尽管未接受降脂治疗)的情况。此外,还对有和没有CHD的亚组进行了评估。
在所有美国高危居民中,LDL-C平均值从1999至2000年的129mg/dL降至2001至2002年的120mg/dL(P = 0.003)。LDL-C<100mg/dL的人群从23%增加到32%(P = 0.003)。LDL-C≥130mg/dL且未接受药物治疗的人群从36%降至27%(P = 0.001)。与因高危等效情况而处于高危的人群相比,CHD亚组在目标达成和改善方面更为有利。
美国高危居民中达到目标的人数急剧增加,且高于治疗阈值的未治疗人群比例下降,这表明在冠心病高危人群的LDL-C管理方面全国范围内有所改善。没有CHD的高危人群改善不太显著,这表明有机会更好地识别和管理这些个体。